CellRev has developed a suite of technologies that offer scalable, quality-controlled, efficient, and affordable processes for adherent cell culture. The platform is designed to make adherent cell culture a viable commercial option for cell and gene therapies and cultured meat. Its processing platform is gaining interest worldwide and the company plans a full launch in 2024. Dr Martina Miotto established CellRev while completing her PhD in Corneal Tissue Engineering and Chris Green is chief executive. The company recently secured external funding to support commercialization. Management says 2024 will be a defining year with a significant product launch and major customer collaborations in the pipeline. CellulaREvolution, founded in 2019, is developing a synthetic peptide coating to eliminate the need for animal-derived serum and a continuous culturing process to cut cell-cultivation costs. The company has built bioreactors designed for continuous growth, and preliminary data indicate these could produce twice as many cells in a given time using a smaller bioreactor than conventional batch culturing. These technologies target two major industry pain points: serum dependence and high cultivation costs. CellulaREvolution reports several ongoing collaborations with cultured meat companies to test specific cell lines, with positive early results. Management has said it is keen to transition some collaborations into sales. The company recently raised external funding to support these development and commercialisation efforts.

Total raised

$4M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2023